This article summarizes existing ethical frameworks for healthcare artificial intelligence (AI) and ambient sensing technology, such as computer vision, and examines their application to improve patient outcomes in the intensive care unit (ICU). Integrating ethical considerations such as privacy, fairness, and autonomy into the lifecycle of an AI tool is necessary to fully harvest AI's potential to deliver safe, high-quality, personalized, and low-cost healthcare services that provide positive experiences for patients, families, and clinicians while improving health outcomes. Drawing from agile science, the article proposes a practical roadmap for clinician and researcher use to identify, integrate, and monitor ethical considerations throughout the lifecycle of an AI tool with the intention to improve patient care. A use case illustrates the application of the agile science-informed roadmap that details the development of a passive digital marker for delirium severity.

AI tools; Agile science; Artificial intelligence; Computer vision; Delirium severity; Ethical frameworks for health care AI; ICU; Passive digital marker.

Disclosures COI: A.A. Gonzalez holds stock in the common stock for NVIDIA, Inc. (NASDAQ: NVDA), Advanced Micro Devices, Inc (NASDAQ, AMD), Microsoft Corp (NASDAQ, MSFT), Advanced Semiconductor Materials Lithography, NV (NASDAQ: ASML), Oracle Corporation (NYSE: ORCL), Apple Computer Inc (NASDAQ: AAPL), and Palantir Technologies Inc (NASDAQ: PLTR). All shares and derivatives contracts were purchased on the open market. Dr Boustani serves as a chief Scientific Officer and co-Founder of BlueAgilis; the Chief Health Officer of DigiCare Realized, Inc; and the Chief Health Officer of Mozyne health, inc. He has equity interest in Blue Agilis, Inc; DigiCare Realized, Inc; and Mozyne Health, Inc. He sold his equity in Preferred Population Health Management LLC; and MyShift, Inc (previously known as RestUp, LLC). He serves as an advisory board member or consultant for Eli Lilly and Co, ; Eisai, Inc; Merck & Co Inc; Biogen Inc; and Genentech Inc. These conflicts have been reviewed by Indiana University and has been appropriately managed to maintain objectivity.